Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
advertise
Legal Help
login/register
You are here
Home
»
companies
» Waldenström’s macroglobulinemia
Waldenström’s macroglobulinemia
Janssen gets EC approval for two new indications of Imbruvica
Janssen gets EC approval for two new indications of Imbruvica
Pharmaceutical Business Review
JNJ
Janssen
Europe
Imbruvica
Waldenström’s macroglobulinemia
chronic lymphocytic leukemia
Flag link:
Upcoming events – Crucial data on zanubrutinib and filgotinib approach
Upcoming events – Crucial data on zanubrutinib and filgotinib approach
EP Vantage
BeiGene
Waldenström’s macroglobulinemia
zanubrutinib
Galapagos
filgotinib
CLE
Sjögren’s syndrome
Flag link:
Jumping ahead of AstraZeneca, AbbVie and J&J get a green light to market Imbruvica/Rituxan combo for rare lymphoma
Jumping ahead of AstraZeneca, AbbVie and J&J get a green light to market Imbruvica/Rituxan combo for rare lymphoma
Endpoints
AbbVie
JNJ
FDA
Imbruvica
Rituxan
Roche
AstraZeneca
non-Hodgkin's lymphoma
Waldenström’s macroglobulinemia
Flag link:
